Search
Col-118
go.drugbank.com/drugs/DB05778InvestigationalCol-118 is a unique formulation and presentation of Brimonidine, which is a selective alpha-2 adrenergic receptor agonist. … It is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue.
NCX 1015
go.drugbank.com/drugs/DB05825ExperimentalNCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.
Prolease-r-hFSH
go.drugbank.com/drugs/DB05826ExperimentalIt provides patients with long term therapeutic benefit from a single administration rather than multiple injections. … Prolease-r-hFSH is a recombinant human follicle stimulating hormone (r-hFSH) with Alkermes' ProLease injectable sustained release drug delivery technology.
Biomed 101
go.drugbank.com/drugs/DB05851InvestigationalBiomed 101 is a solid. Biomed 101 binds to the leukotriene B4 receptor, but does not affect interleukin-2 antitumor activity.
cryopreserved human liver cells
go.drugbank.com/drugs/DB05852ExperimentalVesta Therapeutics is a privately held company developing cell therapeutics for liver repair and regeneration.
TRX1
go.drugbank.com/drugs/DB05863ExperimentalTRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells. … TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.
ETC-1001
go.drugbank.com/drugs/DB05866ExperimentalETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Etazolate
go.drugbank.com/drugs/DB05881InvestigationalEHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.
Synonyms: 1H-PYRAZOLO(3,4-B)PYRIDINE-5-CARBOXYLIC ACID, 1-ETHYL-4-((1-METHYLETHYLIDENE)HYDRAZINO)-, ETHYL ESTERGT 389-255
go.drugbank.com/drugs/DB05894ExperimentalPeptimmune’s lead product GT 389-255, is a novel lipase inhibitor and fat binding hydrogel polymer conjugate for the treatment of obesity which has completed single and multiple ascending dose (SAD and
rhIGFBP-3
go.drugbank.com/drugs/DB05897InvestigationalrhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of human. It is developed by Insmed...